TOKYO, JAPAN – [Date of Publication] – Takeda Pharmaceutical Company Limited has unveiled compelling secondary endpoint data for its investigational oral medication, zasocitinib, for the treatment of plaque psoriasis (PsO). The new findings highlight the drug’s substantial efficacy in addressing PsO in challenging, high-impact areas, including the scalp, palms, and soles, a development that significantly strengthens its potential pathway to regulatory approval. The data, presented at the prestigious 2026 American Academy of Dermatology (AAD) Innovation Academy in New York City, builds upon previous positive results and positions zasocitinib as a promising new oral therapy for patients grappling with this chronic and often debilitating autoimmune disease.
Plaque psoriasis, a chronic, systemic immune-mediated inflammatory condition, is characterized by itchy, painful, disfiguring, and disabling skin lesions. These visible manifestations not only affect a patient’s physical well-being but also carry a profound emotional and psychological burden, impacting daily life and overall quality of existence. Globally, an estimated 64 million individuals live with psoriasis, with plaque psoriasis accounting for the vast majority, approximately 80-90%, of all cases. The persistent and often visible nature of PsO lesions, particularly in areas like the scalp, hands, and feet, can lead to significant social stigma, anxiety, and depression, underscoring the critical need for effective and accessible treatment options.
Takeda’s zasocitinib, a novel oral tyrosine kinase 2 (TYK2) inhibitor, has demonstrated consistent and high rates of skin clearance across these difficult-to-treat sites in two pivotal Phase III clinical trials: NCT06088043 and NCT06108544. These randomized, multi-center, double-blind studies enrolled adult patients with moderate-to-severe plaque psoriasis, aiming to assess the drug’s efficacy and safety profile in a rigorous clinical setting. The latest data focuses on key secondary endpoints, providing a deeper understanding of zasocitinib’s impact on specific patient populations and symptom locations that have historically posed therapeutic challenges.
Chronology of Development and Key Milestones
Takeda’s journey with zasocitinib has been marked by strategic clinical development and the consistent generation of robust data. The company is now poised to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and other global regulatory bodies, signaling a significant step towards potential market entry.
-
December 2025: Takeda initially announced topline primary endpoint data from its Phase III trials. These results indicated that approximately 70% of patients treated with zasocitinib achieved a static Physician Global Assessment (sPGA) score of 0 or 1 (indicating clear or almost clear skin) by week 16. Furthermore, the drug demonstrated a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate as early as week four, with responses continuing to improve through week 24. This initial success laid the foundation for further investigation into the drug’s broader efficacy.
-
[Date of Presentation – Assumed to be within 2026 based on article context]: The company presented detailed secondary endpoint data at the 2026 American Academy of Dermatology (AAD) Innovation Academy. This presentation focused on the drug’s performance in high-impact areas, providing crucial insights into its potential to address specific patient needs.
-
[Ongoing/Upcoming]: Takeda is actively pursuing regulatory submissions, with plans to file NDAs with the FDA and other health authorities commencing in the current fiscal year. Beyond plaque psoriasis, zasocitinib is also under evaluation in Phase III studies for psoriatic arthritis and in Phase II studies for other immune-mediated conditions, including Crohn’s disease, ulcerative colitis, vitiligo, and hidradenitis suppurativa (HS), highlighting its potential as a versatile therapeutic agent.
Supporting Data: Efficacy in High-Impact Areas
The recently released secondary endpoint data provides a detailed picture of zasocitinib’s effectiveness in areas that often present the most significant challenges for patients and clinicians. These areas, due to their visibility and sensitivity, can disproportionately impact a patient’s quality of life.
Scalp Psoriasis:
Scalp psoriasis affects a substantial portion of individuals with plaque psoriasis, impacting approximately half of all patients. The constant itching, scaling, and inflammation can be particularly distressing and difficult to manage, often interfering with daily activities such as hair styling and social interactions.
In the two Phase III trials, zasocitinib demonstrated remarkable success in treating scalp psoriasis. A significant majority of patients treated with the oral TYK2 inhibitor achieved a scalp-specific Physician Global Assessment (ssPGA) score of 0 or 1 (clear or almost clear skin). Specifically:
- In one study, 77% of patients with scalp psoriasis treated with zasocitinib achieved an ssPGA 0/1 response.
- In the second study, 74% of patients achieved the same response.
These figures stand in stark contrast to the placebo group, where only 7% and 13% of patients, respectively, experienced similar levels of skin clearance on the scalp.
For comparative context, zasocitinib also demonstrated a significant advantage over a current oral treatment option. When pitted against Amgen’s Otezla (apremilast), a widely used oral PDE4 inhibitor, zasocitinib showed superior results at week 16:
- 42% of patients treated with zasocitinib achieved ssPGA 0/1 response in one study.
- 30% of patients treated with zasocitinib achieved ssPGA 0/1 response in the other study.
- In contrast, 42% and 30% of patients taking the active comparator (Otezla) achieved the ssPGA 0/1 response in the respective studies.
Palmoplantar Psoriasis:
Psoriasis affecting the palms and soles, known as palmoplantar psoriasis, can be particularly painful and debilitating. It can interfere with basic tasks like walking, gripping objects, and even hand hygiene, leading to significant functional impairment and reduced quality of life.
The data revealed that zasocitinib achieved high rates of response in patients with palmoplantar psoriasis:
- Approximately 70% of patients treated with zasocitinib achieved a hands- and/or feet-specific Physician Global Assessment (hfPGA) score of 0 or 1 (clear or almost clear skin).
- Specifically, 71% and 69% of patients achieved this response in the two studies, respectively.
Again, these results significantly outperformed the placebo group, where only 22% and 10% of patients saw similar clearance.
When compared to Otezla, zasocitinib again demonstrated superior efficacy:
- 71% and 69% of zasocitinib-treated patients achieved hfPGA 0/1 response.
- This compares to 44% and 43% of patients treated with Otezla.
Nail Psoriasis:
Nail psoriasis is a common and often overlooked manifestation of the disease that can significantly impact a patient’s self-esteem and daily activities. It can lead to pain, difficulty with manual tasks, and cosmetic concerns.
Zasocitinib also delivered statistically significant improvements in the Nail Psoriasis Severity Index (NAPSI) compared to placebo at week 16. Importantly, these positive responses were sustained through week 24 in both studies, indicating a durable effect of the treatment.
Official Responses and Expert Opinions
The promising data has garnered positive reactions from both the pharmaceutical company and leading dermatological experts.
Dr. Leon Kircik, founder and medical director of Skin Sciences and Physicians Skin Care in Louisville, KY, and a principal investigator for the LATITUDE PsO studies, expressed his enthusiasm for the findings. "Despite advances in psoriasis care, many patients continue to experience persistent symptoms, especially in highly visible or sensitive areas like the scalp – impacting about half of patients with psoriasis – which can disproportionately affect daily life," Dr. Kircik stated. "These findings show that zasocitinib delivered consistently clear skin across the hardest-to-treat areas, including the scalp, nails, palms and soles, reinforcing its potential to become a leading oral treatment option for patients seeking meaningful, whole-body skin clearance."
Takeda’s commitment to addressing unmet needs in psoriasis treatment is evident in its ongoing development program for zasocitinib. The company’s proactive approach to seeking regulatory approval, coupled with the robust clinical data, suggests a strong confidence in the drug’s therapeutic profile.
Implications for the Plaque Psoriasis Market
The landscape of plaque psoriasis treatment is highly competitive, with established players and emerging therapies vying for market share. Zasocitinib’s potential entry into this market, particularly with its demonstrated efficacy in high-impact areas, could significantly reshape treatment paradigms.
Currently, the PsO market in the US is dominated by Sotyktu (deucravacitinib) from Bristol Myers Squibb (BMS) and Skyrizi (risankizumab) from AbbVie. Sotyktu shares a similar mechanism of action with zasocitinib as a TYK2 inhibitor. Skyrizi, an injectable monoclonal antibody, targets IL-23.
Takeda has already demonstrated zasocitinib’s superiority over Sotyktu in a head-to-head Phase III LATITUDE Atlas study (NCT06973291). In this trial, zasocitinib achieved statistical superiority over Sotyktu in the PASI 100 response rate at week 16, with over 35% of zasocitinib patients achieving this endpoint – more than 2.5 times the response rate seen with Sotyktu. Furthermore, zasocitinib also showed statistical superiority over Sotyktu for all key secondary endpoints, including PASI 90 response and sPGA 0 at week 16.
The market is also witnessing new entrants. Johnson & Johnson (J&J) recently gained FDA approval in March 2026 for its oral targeted peptide, Icotyde (icotrokinra), which precisely blocks the IL-23 receptor. Icotyde is positioned as a successor to J&J’s Stelara (ustekinumab), an IL-23 inhibitor that lost core patent exclusivity in 2023. J&J also offers the injectable Tremfya (guselkumab) for psoriasis.
The projected growth of the psoriasis drug market further underscores the significance of these developments. GlobalData forecasts that PsO drug sales across seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) will reach $11.56 billion by 2030. In this expanding market, zasocitinib’s profile as an effective oral therapy for challenging psoriasis manifestations could carve out a substantial niche. Its potential to offer a convenient, once-daily oral option with demonstrated efficacy in areas like the scalp, palms, and soles addresses a critical unmet need for many patients seeking comprehensive disease control and improved quality of life.
The comprehensive data presented by Takeda, showcasing zasocitinib’s consistent and significant impact on high-impact psoriasis areas, positions the drug as a strong contender in the evolving landscape of psoriasis therapeutics. With regulatory submissions underway, the medical community and patients alike will be keenly awaiting the outcome of these reviews, hopeful for a new and effective oral treatment option for plaque psoriasis.
About the Author
